MCID: LNG064
MIFTS: 64

Lung Cancer Susceptibility 3

Categories: Rare diseases, Cancer diseases, Respiratory diseases

Aliases & Classifications for Lung Cancer Susceptibility 3

MalaCards integrated aliases for Lung Cancer Susceptibility 3:

Name: Lung Cancer Susceptibility 3 53 13 69
Adenocarcinoma of Lung 53 12 72 28 41 69
Lung Adenocarcinoma 37 12 49 28 14
Adenocarcinoma of Lung, Susceptibility to 53
Bronchogenic Lung Adenocarcinoma 12
Non-Small Cell Adenocarcinoma 69
Nonsmall Cell Adenocarcinoma 12
Adenocarcinoma Lung 51
Lncr3 53

Classifications:



External Ids:

OMIM 53 612571
Disease Ontology 12 DOID:3910
MeSH 41 C538231
NCIt 46 C27745 C3512
SNOMED-CT 64 254626006

Summaries for Lung Cancer Susceptibility 3

NIH Rare Diseases : 49 Lung adenocarcinoma is a cancer that occurs due to abnormal and uncontrolled cell growth in the lungs. It is a subtype of non-small cell lung cancer that is often diagnosed in an outer area of the lung. Early lung cancers may not be associated with any signs and symptoms. As the condition progresses, affected people can experience chest pain, a persistent cough, fatigue, coughing up blood, loss of appetite, unexplained weight loss, shortness of breath, and/or wheezing. The underlying cause of lung adenocarcinoma is generally unknown; however, risk factors for developing a lung cancer include smoking; exposure to secondhand smoke and other toxic chemicals; a family history of lung cancer; previous radiation treatment to the chest or breast; and HIV infection. Treatment varies based on the severity of the condition, the associated signs and symptoms and the affected person's overall health. It may include a combination of surgery, radiation therapy, chemotherapy, targeted therapy, and/or watchful waiting. Last updated: 2/10/2016

MalaCards based summary : Lung Cancer Susceptibility 3, also known as adenocarcinoma of lung, is related to bronchiolo-alveolar adenocarcinoma and lung cancer. An important gene associated with Lung Cancer Susceptibility 3 is HRAS (HRas Proto-Oncogene, GTPase), and among its related pathways/superpathways are ERK Signaling and GPCR Pathway. The drugs Gilotrif and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include lung, breast and endothelial, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A non-small cell lung carcinoma that derives from epithelial cells of glandular origin.

Wikipedia : 72 Adenocarcinoma of the lung (pulmonary adenocarcinoma) is a common histological form of lung cancer that... more...

Description from OMIM: 612571

Related Diseases for Lung Cancer Susceptibility 3

Diseases in the Lung Cancer Susceptibility 3 family:

Lung Cancer Susceptibility 1 Lung Cancer Susceptibility 4
Lung Cancer Susceptibility 5

Diseases related to Lung Cancer Susceptibility 3 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 243)
# Related Disease Score Top Affiliating Genes
1 bronchiolo-alveolar adenocarcinoma 33.6 EGFR KRAS KRT7 NKX2-1
2 lung cancer 33.1 BRAF CASP3 CDH1 CDK4 EGFR ERBB2
3 adenocarcinoma 31.5 BRAF CDH1 EGFR ERBB2 HRAS KRAS
4 papillary adenocarcinoma 30.7 CDH1 ERBB2 KRT7 NKX2-1
5 mucinous adenocarcinoma 30.6 EGFR KRAS KRT20 KRT7 NKX2-1 TP53
6 squamous cell carcinoma 30.5 BRAF CDH1 EGFR ERBB2 HRAS KRT7
7 lung occult adenocarcinoma 10.9
8 lung cancer susceptibility 1 10.9
9 tumor suppressor gene on chromosome 11 10.9 BRAF EGFR ERBB2 KRAS
10 spitz nevus 10.9 BRAF HRAS TP53
11 pulmonic stenosis 10.9 BRAF HRAS KRAS RAF1
12 acneiform dermatitis 10.9 EGFR ERBB2 HRAS KRAS
13 adenosquamous cell lung carcinoma 10.9 EGFR ERBB2 HRAS KRAS
14 paronychia 10.9 EGFR HRAS KRAS
15 lung adenoid cystic carcinoma 10.9 EGFR HRAS KRAS NKX2-1
16 uterine carcinosarcoma 10.9 EGFR ERBB2 HRAS TP53
17 small intestinal adenocarcinoma 10.9 BRAF EGFR ERBB2 KRAS
18 exanthem 10.9 EGFR ERBB2 HRAS KRAS
19 hyperplastic polyposis syndrome 10.9 BRAF KRAS TP53
20 oncocytic breast carcinoma 10.9 EGFR ERBB2 KRT7
21 nasal cavity adenocarcinoma 10.9 HRAS KRAS KRT7 TP53
22 liver angiosarcoma 10.9 CDK4 HRAS KRAS TP53
23 pulmonary blastoma 10.9 EGFR KRAS NKX2-1 TP53
24 struma ovarii 10.9 BRAF KRAS NKX2-1
25 lung acinar adenocarcinoma 10.9 KRT20 KRT7 NKX2-1
26 ovary adenocarcinoma 10.9 HRAS KRAS KRT7 TP53
27 biliary tract neoplasm 10.9 HRAS KRAS KRT7 TP53
28 pleomorphic carcinoma 10.9 EGFR KRT7 NKX2-1 TP53
29 respiratory system benign neoplasm 10.9 KRAS NKX2-1 RAF1
30 vaginal benign neoplasm 10.9 KRT20 KRT7 STK11
31 vaginal adenoma 10.9 KRT20 KRT7 STK11
32 ampulla of vater neoplasm 10.9 HRAS KRAS KRT20 KRT7
33 vaginal tubulovillous adenoma 10.9 KRT20 KRT7 STK11
34 microglandular adenosis 10.9 EGFR ERBB2 TP53
35 breast squamous cell carcinoma 10.9 CDH1 EGFR ERBB2
36 breast metaplastic carcinoma 10.9 CDH1 EGFR ERBB2 TP53
37 krukenberg carcinoma 10.9 KRT20 KRT7 NAPSA
38 pilocytic astrocytoma 10.9 BRAF CDK4 HRAS KRAS RAF1
39 pre-malignant neoplasm 10.9 CDH1 EGFR ERBB2 TP53
40 papillary adenoma 10.9 KRT7 NAPSA NKX2-1
41 primary peritoneal carcinoma 10.9 EGFR ERBB2 TP53 VEGFA
42 mature teratoma 10.9 BRAF KRAS TP53
43 cecum adenocarcinoma 10.9 HRAS KRAS KRT20 KRT7
44 small cell carcinoma of the bladder 10.9 KRT20 KRT7 NKX2-1
45 mammary paget's disease 10.9 EGFR ERBB2 KRT20 KRT7
46 mixed cell type cancer 10.9 ERBB2 HRAS KRAS KRT7 TP53
47 vulval paget's disease 10.9 ERBB2 KRT20 KRT7
48 horseshoe kidney 10.9 EGFR KRT20 KRT7 NKX2-1
49 papillary serous adenocarcinoma 10.9 KRT20 KRT7 NKX2-1 TP53
50 in situ carcinoma 10.9 CDH1 EGFR ERBB2 TP53

Graphical network of the top 20 diseases related to Lung Cancer Susceptibility 3:



Diseases related to Lung Cancer Susceptibility 3

Symptoms & Phenotypes for Lung Cancer Susceptibility 3

Clinical features from OMIM:

612571

GenomeRNAi Phenotypes related to Lung Cancer Susceptibility 3 according to GeneCards Suite gene sharing:

25 (show all 34)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.67 EGFR HRAS KRAS BRAF
2 Decreased viability GR00106-A-0 10.67 KRAS
3 Decreased viability GR00221-A-1 10.67 EGFR HRAS KRAS CDH1 RAF1
4 Decreased viability GR00221-A-2 10.67 HRAS KRAS RAF1
5 Decreased viability GR00221-A-3 10.67 HRAS
6 Decreased viability GR00221-A-4 10.67 EGFR BRAF
7 Decreased viability GR00231-A 10.67 RAF1
8 Decreased viability GR00301-A 10.67 KRAS BRAF CDH1 RAF1
9 Decreased viability GR00381-A-1 10.67 KRAS BRAF
10 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.85 CDK4 EGFR ERBB2 HRAS STK11 VEGFA
11 Decreased cell migration GR00055-A-1 9.83 HRAS KRAS BRAF CDK4 EGFR
12 Decreased cella89culturea89derived Hepatitis C virus (HCVcc GR00234-A-2 9.71 BRAF CDK4 EGFR STK11
13 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.66 NAPSA
14 Increased shRNA abundance (Z-score > 2) GR00366-A-110 9.66 ACTR3B
15 Increased shRNA abundance (Z-score > 2) GR00366-A-115 9.66 CDK4
16 Increased shRNA abundance (Z-score > 2) GR00366-A-118 9.66 EGFR
17 Increased shRNA abundance (Z-score > 2) GR00366-A-121 9.66 EGFR
18 Increased shRNA abundance (Z-score > 2) GR00366-A-151 9.66 ACTR3B
19 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.66 ACTR3B
20 Increased shRNA abundance (Z-score > 2) GR00366-A-189 9.66 NAPSA
21 Increased shRNA abundance (Z-score > 2) GR00366-A-190 9.66 EGFR
22 Increased shRNA abundance (Z-score > 2) GR00366-A-21 9.66 ACTR3B CDK4 EGFR NAPSA
23 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.66 EGFR
24 Increased shRNA abundance (Z-score > 2) GR00366-A-41 9.66 ACTR3B
25 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.66 CDK4
26 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.66 EGFR
27 Increased shRNA abundance (Z-score > 2) GR00366-A-45 9.66 NAPSA
28 Increased shRNA abundance (Z-score > 2) GR00366-A-46 9.66 CDK4
29 Increased shRNA abundance (Z-score > 2) GR00366-A-52 9.66 NAPSA
30 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.66 CDK4 EGFR
31 Decreased Hepatitis C Virus pseudoparticles (HCVpp GR00234-A-1 9.62 BRAF CDK4 EGFR STK11
32 Decreased viability with paclitaxel GR00179-A-1 9.46 ERBB2 CASP3 EGFR
33 Decreased viability with paclitaxel GR00179-A-3 9.46 EGFR
34 Increased cell viability after pRB stimulation GR00230-A-1 9.26 CDK4 EGFR ERBB2 STK11

MGI Mouse Phenotypes related to Lung Cancer Susceptibility 3:

43 (show all 25)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.49 EGFR ERBB2 HRAS KRAS NKX2-1 PRKN
2 cellular MP:0005384 10.49 EGFR ERBB2 KRAS BRAF CASP3 CDH1
3 homeostasis/metabolism MP:0005376 10.46 HRAS KRAS KRT7 NKX2-1 PRKN RAF1
4 endocrine/exocrine gland MP:0005379 10.43 BRAF CASP3 CDH1 CDK4 EGFR ERBB2
5 growth/size/body region MP:0005378 10.42 BRAF CASP3 CDH1 CDK4 EGFR ERBB2
6 digestive/alimentary MP:0005381 10.41 CDK4 EGFR ERBB2 HRAS KRAS NKX2-1
7 behavior/neurological MP:0005386 10.4 BRAF CASP3 CDK4 ERBB2 HRAS KRAS
8 mortality/aging MP:0010768 10.39 CASP3 CDH1 CDK4 EGFR ERBB2 HRAS
9 integument MP:0010771 10.35 BRAF CASP3 CDH1 CDK4 EGFR ERBB2
10 craniofacial MP:0005382 10.3 BRAF CASP3 EGFR ERBB2 HRAS KRAS
11 embryo MP:0005380 10.29 VEGFA BRAF CDH1 CDK4 EGFR ERBB2
12 immune system MP:0005387 10.29 CDK4 EGFR KRAS RAF1 RASSF1 STK11
13 neoplasm MP:0002006 10.29 BRAF CDH1 CDK4 EGFR ERBB2 HRAS
14 nervous system MP:0003631 10.27 ERBB2 HRAS BRAF CASP3 CDK4 EGFR
15 normal MP:0002873 10.25 BRAF CDH1 CDK4 EGFR ERBB2 HRAS
16 muscle MP:0005369 10.24 BRAF CASP3 CDK4 EGFR ERBB2 KRAS
17 liver/biliary system MP:0005370 10.18 BRAF CDK4 EGFR KRAS RAF1 RASSF1
18 no phenotypic analysis MP:0003012 10.17 CASP3 CDH1 EGFR HRAS KRAS NKX2-1
19 hearing/vestibular/ear MP:0005377 10.04 BRAF CASP3 EGFR KRAS RAF1 TP53
20 renal/urinary system MP:0005367 10.02 TP53 VEGFA BRAF CASP3 CDK4 EGFR
21 reproductive system MP:0005389 10 CASP3 CDH1 CDK4 EGFR ERBB2 KRAS
22 respiratory system MP:0005388 9.93 VEGFA BRAF CASP3 EGFR ERBB2 HRAS
23 pigmentation MP:0001186 9.85 BRAF CASP3 CDK4 EGFR KRAS TP53
24 skeleton MP:0005390 9.7 BRAF CASP3 EGFR ERBB2 HRAS KRAS
25 vision/eye MP:0005391 9.28 BRAF CASP3 CDK4 EGFR KRAS RAF1

Drugs & Therapeutics for Lung Cancer Susceptibility 3

FDA approved drugs:

# Drug Name Active Ingredient(s) 17 Company Approval Date
1
Gilotrif 17 45 AFATINIB DIMALEATE Boehringer Ingelheim July 2013

Drugs for Lung Cancer Susceptibility 3 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 191)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 38904 498142
2
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 2767 441203 84093
3
Pemetrexed Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 150399-23-8, 137281-23-3 60843 446556
4
Gefitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 184475-35-2 123631
5
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59-30-3 6037
6
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 143 6006
7
Docetaxel Approved May 1996, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 114977-28-5 148124 9877265
8 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
9 Mitogens Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
10
Erlotinib Hydrochloride Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 183319-69-9 176871
11 Folic Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
12 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 Protein Kinase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
14 Vitamin B Complex Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Angiogenesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
16 Angiogenesis Modulating Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
17 Endostatins Phase 4 71581480
18 Folate Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
19 tyrosine Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 Vitamin B9 Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
21
Gemcitabine Approved Phase 3,Phase 2,Phase 1,Not Applicable 95058-81-4 60750
22
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
23
Vinorelbine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 71486-22-1 44424639 60780
24
Mesna Approved, Investigational Phase 3,Phase 2 3375-50-6 598
25
Loperamide Approved Phase 3 53179-11-6 3955
26
Bevacizumab Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 216974-75-3
27
Etoposide Approved Phase 3,Phase 2,Phase 1,Not Applicable 33419-42-0 36462
28
Vinblastine Approved Phase 3,Phase 2,Phase 1 865-21-4 241903 13342
29
Vindesine Approved, Investigational Phase 3 53643-48-4, 59917-39-4 40839
30
Hydroxocobalamin Approved Phase 3,Not Applicable 13422-51-0 5460373 44475014 11953898
31
Cetuximab Approved Phase 3,Phase 1,Phase 2 205923-56-4 56842117 2333
32
Crizotinib Approved Phase 3,Phase 2,Phase 1 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
33
Lenograstim Approved, Investigational Phase 3,Phase 2,Not Applicable 135968-09-1
34
Celecoxib Approved, Investigational Phase 3,Phase 2 169590-42-5 2662
35
Naloxegol Approved Phase 3 854601-70-0
36
Ceritinib Approved Phase 3,Phase 2 1032900-25-6
37
Xylometazoline Approved, Investigational Phase 3 526-36-3 5709
38
Cytarabine Approved, Investigational Phase 3 147-94-4 6253
39
Cyanocobalamin Approved, Nutraceutical Phase 3,Not Applicable 68-19-9 44176380
40
Methylcobalamin Approved, Experimental, Investigational, Nutraceutical Phase 3,Not Applicable 13422-55-4
41
Tirapazamine Investigational Phase 3,Phase 1 27314-97-2
42 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Not Applicable
43 Antimetabolites Phase 3,Phase 2,Phase 1,Not Applicable
44 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1,Not Applicable
45 Antiviral Agents Phase 3,Phase 2,Phase 1,Not Applicable
46 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Not Applicable
47 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1,Not Applicable
48 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1,Not Applicable
49 Protective Agents Phase 3,Phase 2
50 Gastrointestinal Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 356)

# Name Status NCT ID Phase Drugs
1 Icotinib as the Adjunctive Treatment After Surgery in Stage I-IIIB Lung Adenocarcinoma Patients With EGFR Gene Mutation Unknown status NCT02283424 Phase 4 Icotinib;chemotherapy (Carboplatin and Docetaxel)
2 Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma Unknown status NCT02103257 Phase 4 Sequential Icotinib Plus Chemotherapy;Icotinib
3 Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung Cancer Unknown status NCT02031601 Phase 4 Erlotinib;Gefitinib;Icotinib;Docetaxel;Pemetrexed;Platinum (cisplatin or carboplatin);Erlotinib;Gefitinib;Icotinib
4 A Study of Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations Completed NCT01609543 Phase 4 erlotinib [Tarceva]
5 Endostar Durative Transfusion Combined With Chemotherapy in the Treatment of Advanced Lung Adenocarcinoma Recruiting NCT02804646 Phase 4 recombinant human endostatin;pemetrexed plus cisplatin or carboplatin
6 Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma Recruiting NCT01665417 Phase 4 Experimental;Chemotherapy;Chemotherapy
7 Clinical Trial of Erlotinib and Pemetrexed for Maintenance Treatment in Lung Adenocarcinoma Not yet recruiting NCT02399566 Phase 4 Erlotinib, Pemetrexed
8 Pemetrexed (ALIMTA) and Gefitinib (IRESSA®) in Never-Smoker and Adenocarcinoma Patients With Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy Unknown status NCT01066195 Phase 3 iressa;alimta
9 Radiation Therapy to the Brain or Observation in Preventing Brain Metastases in Patients With Advanced Non-Small Cell Lung Cancer Unknown status NCT00955695 Phase 3 erlotinib hydrochloride;gefitinib
10 First-line Gefitinib Versus Chemotherapy for Lung Adenocarcinoma in Never Smoker Completed NCT00455936 Phase 3 Gefitinib
11 Phase 3 Study of Tavocept Versus Placebo in Patients With Newly Diagnosed or Relapsed Advanced Primary Adenocarcinoma of the Lung Treated With Docetaxel or Paclitaxel Plus Cisplatin Completed NCT00966914 Phase 3 Tavocept(BNP7787) in combination with cisplatin and either docetaxel or paclitaxel;Placebo in combination with cisplatin and docetaxel or paclitaxel
12 BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC) Completed NCT01121393 Phase 3 Gemcitabine+Cisplatin;BIBW 2992
13 BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation Completed NCT00949650 Phase 3 Pemetrexed;BIBW 2992;Cisplatin
14 ADAM-Afatinib Diarrhea Assessment and Management Completed NCT01814553 Phase 3 afatinib;loperamide
15 Intercalating and Maintenance Use of Iressa Versus Chemotherapy in Selected Advanced Non Small Cell Lung Cancer Completed NCT01404260 Phase 3 Gefitinib;Gemcitabine +Carboplatin
16 Carboplatin, Paclitaxel, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed During Surgery Completed NCT00003387 Phase 3 carboplatin;chemotherapy;paclitaxel
17 Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer Completed NCT00021060 Phase 2, Phase 3 paclitaxel;carboplatin
18 Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery Completed NCT00020709 Phase 3 cisplatin;docetaxel;etoposide;gefitinib
19 Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery Completed NCT00005838 Phase 3 shark cartilage extract AE-941;cisplatin;vinorelbine tartrate;carboplatin;paclitaxel
20 Surgery With or Without Chemotherapy in Treating Patients With Stage I Non-small Cell Lung Cancer Completed NCT00002852 Phase 3 paclitaxel;carboplatin
21 Chemotherapy Plus Radiation Therapy With or Without Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer Completed NCT00002550 Phase 3 cisplatin;etoposide
22 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Can Not Be Surgically Removed Completed NCT00003235 Phase 3 carboplatin;paclitaxel
23 Lymph Node Removal in Treating Patients With Stage I or Stage II Non-small Cell Lung Cancer Completed NCT00003831 Phase 3
24 Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery Completed NCT00049543 Phase 3 gefitinib
25 Vinorelbine, Gemcitabine, and Docetaxel Compared With Paclitaxel and Carboplatin in Treating Patients With Advanced Non-Small Cell Lung Cancer Completed NCT00079287 Phase 3 carboplatin;docetaxel;gemcitabine hydrochloride;paclitaxel;vinorelbine tartrate
26 Chemotherapy Followed by Surgery or Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer Completed NCT00002623 Phase 3 carboplatin;cisplatin
27 Chemotherapy and Radiation Therapy With or Without Epoetin Alfa in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer Completed NCT00028938 Phase 3 carboplatin;paclitaxel
28 Combination Chemotherapy With or Without Tirapazamine in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer Completed NCT00006484 Phase 3 carboplatin;paclitaxel;tirapazamine
29 Prognostic Study of Metastases in Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer That Can Be Removed by Surgery Completed NCT00003901 Phase 3
30 Radiation Therapy to Relieve Symptoms in Patients With Non-small Cell Lung Cancer Completed NCT00003685 Phase 3
31 Paclitaxel With or Without Carboplatin in Treating Patients With Advanced Non-small Cell Lung Cancer Completed NCT00003117 Phase 3 carboplatin;paclitaxel
32 Combination Chemotherapy Compared With No Treatment Following Surgery in Treating Patients With Non-small Cell Lung Cancer Completed NCT00002823 Phase 3 cisplatin;etoposide;vinblastine sulfate;vindesine;vinorelbine tartrate
33 An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation Completed NCT00132704 Phase 3
34 Adjuvant Chemotherapy for High Post-operative Recurrence Risk Stage pI Lung Adenocarcinoma Recruiting NCT03380468 Phase 2, Phase 3 cisplatin plus pemetrexed
35 Pemetrexed Combined With Synchronous Gefitinib as Adjuvent Therapy in Patient With EGFR Mutant Lung Adenocarcinoma Recruiting NCT02518802 Phase 3 Gefitinib;Pemetrexed
36 Stereotactic Body Radiation Therapy (SBRT) in Newly Diagnosed Advanced Staged Lung Adenocarcinoma (Sindas) Recruiting NCT02893332 Phase 3 TKI (Gefitinib or Tarceva )
37 Multicenter Randomized Controlled Trial Adjuvant Chemotherapy vs Observation in pStage Ib Lung Adenocarcinoma Recruiting NCT02281708 Phase 3 vinorelbine plus cisplatin
38 Icotinib Versus Placebo as Adjuvant Therapy in EGFR-mutant Lung Adenocarcinoma Recruiting NCT02125240 Phase 3 Icotinib;Placebo
39 To Evaluate the Optimal Timing of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer Recruiting NCT02974426 Phase 3 Platinum-based two drug chemotherapy (cisplatin/carboplatin + vinorelbine or cisplatin/carboplatin + pemetrexed regimen)
40 Naloxegol in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer Recruiting NCT03087708 Phase 3 Naloxegol
41 Therapeutic Strategies in Patients With Non-squamous Non-small Cell Lung Cancer With Brain Metastases Recruiting NCT02162537 Phase 3 Cisplatin;Pemetrexed;Bevacizumab
42 Erlotinib Versus Gemcitabine/Cisplatin as (Neo)Adjuvant Treatment in Non-small Cell Lung Cancer Recruiting NCT01407822 Phase 2, Phase 3 Erlotinib;Gemcitabine/cisplatin
43 Icotinib Versus First-line Chemotherapy Plus Maintenance Treatment in EGFR Positive Lung Adenocarcinoma Patients Active, not recruiting NCT01719536 Phase 3 Icotinib;Chemotherapy
44 S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer Active, not recruiting NCT00946712 Phase 3 Carboplatin;Paclitaxel
45 Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer Active, not recruiting NCT00499330 Phase 3
46 Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Active, not recruiting NCT01107626 Phase 3 pemetrexed disodium
47 LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib Active, not recruiting NCT01828112 Phase 3 Ceritinib;pemetrexed;docetaxel
48 LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer Active, not recruiting NCT01828099 Phase 3 Ceritinib;Pemetrexed;Cisplatin;Carboplatin
49 Clinical Study of YYJD Decoction Combined With Gefitinib in Advanced Pulmonary Adenocarcinoma Enrolling by invitation NCT02929693 Phase 3 gefitinib;Yiqi-yangyin-jiedu decoction;placebo
50 Clinical Study of Chinese Medicine Plus Targeted Therapy Maintenance in Advanced Pulmonary Adenocarcinoma Enrolling by invitation NCT02889692 Phase 3 YiQiFang;YangYinFang;YiQiYangYinFang;placebo granules;Erlotinib®;Gefitinib®;Icotinib®

Search NIH Clinical Center for Lung Cancer Susceptibility 3

Cochrane evidence based reviews: adenocarcinoma of lung

Genetic Tests for Lung Cancer Susceptibility 3

Genetic tests related to Lung Cancer Susceptibility 3:

# Genetic test Affiliating Genes
1 Adenocarcinoma of Lung 28
2 Lung Adenocarcinoma 28

Anatomical Context for Lung Cancer Susceptibility 3

MalaCards organs/tissues related to Lung Cancer Susceptibility 3:

38
Lung, Breast, Endothelial, Testes, Adipocyte

Publications for Lung Cancer Susceptibility 3

Articles related to Lung Cancer Susceptibility 3:

(show all 27)
# Title Authors Year
1
Adenocarcinoma of Lung Presenting as Lambert-Eaton Myasthenic Syndrome. ( 28785598 )
2017
2
Clinical characteristics and programmed cell death ligand-1 expression in adenocarcinoma<i>in situ</i>and minimally invasive adenocarcinoma of lung. ( 29228652 )
2017
3
Central retinal artery occlusion, an early sign of crizotinib resistance in an alk positive adenocarcinoma of lung: A rare case report. ( 27606884 )
2016
4
Discordance of Mutation Statuses of Epidermal Growth Factor Receptor and K-ras between Primary Adenocarcinoma of Lung and Brain Metastasis. ( 27070580 )
2016
5
Metachronous Primary Adenocarcinoma of Lung During Adjuvant Imatinib Mesylate Therapy for Gastrointestinal Stromal Tumor of Stomach: A Case Report. ( 26356712 )
2015
6
Enhancement of tumor initiation and expression of KCNMA1, MORF4L2 and ASPM genes in the adenocarcinoma of lung xenograft after vorinostat treatment. ( 25796627 )
2015
7
Adenocarcinoma of Lung Presenting as Interstitial Lung Disease. ( 27164733 )
2015
8
A fine decision tree consisted of CK5/6, IMP3 and TTF1 for cytological diagnosis among reactive mesothelial cells, metastatic adenocarcinoma of lung and non-lung origin in pleural effusion. ( 25337222 )
2014
9
Tumor to tumor metastasis: Adenocarcinoma of lung metastatic to meningioma. ( 25370552 )
2014
10
Utilization of cell-transferred cytologic smears in detection of EGFR and KRAS mutation on adenocarcinoma of lung. ( 24336155 )
2013
11
A meta-analysis of the association between glutathione S-transferase P1 gene polymorphism and the risk of adenocarcinomas of lung cancer. ( 23736019 )
2013
12
Acquired xanthine dehydrogenase expression shortens survival in patients with resected adenocarcinoma of lung. ( 22678977 )
2012
13
Mucinous adenocarcinoma of lung presenting as oral metastases: a case report and literature review. ( 21146088 )
2011
14
Clinical impact of phosphorylated signal transducer and activator of transcription 3, epidermal growth factor receptor, p53, and vascular endothelial growth factor receptor 1 expression in resected adenocarcinoma of lung by using tissue microarray. ( 20052735 )
2010
15
Expression of CUB domain containing protein (CDCP1) is correlated with prognosis and survival of patients with adenocarcinoma of lung. ( 19077003 )
2009
16
[The effect of seawater on expression of protease-activated receptor 2 in adenocarcinoma of lung cell line A549 cells]. ( 19930877 )
2009
17
Metachronus malignant rhabdoid tumor of the ileum and adenocarcinoma of lung: a unique case report. ( 18164418 )
2008
18
CD63 as a biomarker for predicting the clinical outcomes in adenocarcinoma of lung. ( 17350713 )
2007
19
Primary polymorphous low-grade adenocarcinoma of lung treated by sleeve bronchial resection: a case report. ( 17449954 )
2007
20
Somatic mutations in epidermal growth factor receptor underlying complete responsiveness to gefitinib in a Taiwanese female patient with metastatic adenocarcinoma of lung. ( 16027522 )
2005
21
[Expression of PKB protein in human squamous-cell carcinoma and adenocarcinoma of lung]. ( 15946565 )
2005
22
The expression of c-myc, bcl-2 and p53 proteins in adenocarcinomas of lung. ( 20396555 )
2004
23
[Use of thyroid transcription factor-1, surfacfant protein-B, cytokeratin 7 and cytokeratin 20 in discrimination between primary and metastatic adenocarcinoma of lung]. ( 12930693 )
2003
24
Intercellular adhesion molecules (ICAM-1, VCAM-1, and LFA-1) in adenocarcinoma of lung. Technical aspects. ( 12415699 )
2003
25
The value of thyroid transcription factor-1 in cytologic preparations as a marker for metastatic adenocarcinoma of lung origin. ( 11601132 )
2001
26
Prognostic significance of HER-2/neu overexpression in stage I adenocarcinoma of lung. ( 9800799 )
1998
27
Papillary adenocarcinoma of lung with psammoma bodies: report of a case derived from type II pneumocytes. ( 3758952 )
1986

Variations for Lung Cancer Susceptibility 3

ClinVar genetic disease variations for Lung Cancer Susceptibility 3:

6 (show top 50) (show all 117)
# Gene Variation Type Significance SNP ID Assembly Location
1 SMAD4 NM_005359.5(SMAD4): c.1081C> T (p.Arg361Cys) single nucleotide variant Pathogenic/Likely pathogenic rs80338963 GRCh37 Chromosome 18, 48591918: 48591918
2 SMAD4 NM_005359.5(SMAD4): c.1157G> A (p.Gly386Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121912580 GRCh37 Chromosome 18, 48593406: 48593406
3 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic/Likely pathogenic rs121912651 GRCh37 Chromosome 17, 7577539: 7577539
4 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic/Likely pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
5 TP53 NM_000546.5(TP53): c.725G> A (p.Cys242Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121912655 GRCh37 Chromosome 17, 7577556: 7577556
6 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121912656 GRCh37 Chromosome 17, 7577547: 7577547
7 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
8 TP53 NM_000546.5(TP53): c.814G> T (p.Val272Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121912657 GRCh37 Chromosome 17, 7577124: 7577124
9 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Pathogenic/Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
10 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
11 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
12 TP53 NM_000546.5(TP53): c.451C> A (p.Pro151Thr) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
13 TP53 NM_000546.5(TP53): c.451C> T (p.Pro151Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
14 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic/Likely pathogenic rs121912666 GRCh37 Chromosome 17, 7578190: 7578190
15 KRAS NM_033360.3(KRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913530 GRCh37 Chromosome 12, 25398285: 25398285
16 HRAS NM_005343.3(HRAS): c.34G> A (p.Gly12Ser) single nucleotide variant Pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
17 HRAS NM_005343.3(HRAS): c.35G> C (p.Gly12Ala) single nucleotide variant Pathogenic/Likely pathogenic rs104894230 GRCh37 Chromosome 11, 534288: 534288
18 HRAS NM_005343.3(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic rs104894228 GRCh37 Chromosome 11, 534286: 534286
19 HRAS NM_005343.3(HRAS): c.436G> A (p.Ala146Thr) single nucleotide variant Pathogenic/Likely pathogenic rs104894231 GRCh37 Chromosome 11, 533467: 533467
20 HRAS NM_005343.3(HRAS): c.437C> T (p.Ala146Val) single nucleotide variant Pathogenic/Likely pathogenic rs121917759 GRCh37 Chromosome 11, 533466: 533466
21 HRAS NM_005343.3(HRAS): c.34G> T (p.Gly12Cys) single nucleotide variant Pathogenic/Likely pathogenic rs104894229 GRCh37 Chromosome 11, 534289: 534289
22 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
23 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
24 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
25 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
26 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
27 ERBB2 NM_001005862.2(ERBB2): c.2223_2234dupATACGTGATGGC (p.Ala745_Gly746insTyrValMetAla) duplication Pathogenic/Likely pathogenic rs397516975 GRCh37 Chromosome 17, 37880984: 37880995
28 ERBB2 NM_004448.3(ERBB2): c.2328_2336dupTGTGGGCTC (p.Ser779_Pro780insValGlySer) duplication Pathogenic rs587776805 GRCh37 Chromosome 17, 37880999: 37881007
29 ERBB2 NM_001005862.2(ERBB2): c.2173_2174delTTinsCC (p.Leu725Pro) indel Pathogenic/Likely pathogenic rs121913469 GRCh37 Chromosome 17, 37880219: 37880220
30 NRAS NM_002524.4(NRAS): c.182A> G (p.Gln61Arg) single nucleotide variant Pathogenic/Likely pathogenic rs11554290 GRCh37 Chromosome 1, 115256529: 115256529
31 RAF1 NM_002880.3(RAF1): c.770C> T (p.Ser257Leu) single nucleotide variant Pathogenic rs80338796 GRCh37 Chromosome 3, 12645699: 12645699
32 BRAF NM_004333.4(BRAF): c.1799T> A (p.Val600Glu) single nucleotide variant Pathogenic/Likely pathogenic rs113488022 GRCh37 Chromosome 7, 140453136: 140453136
33 BRAF NM_004333.4(BRAF): c.1801A> G (p.Lys601Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913364 GRCh37 Chromosome 7, 140453134: 140453134
34 BRAF NM_004333.4(BRAF): c.1397G> T (p.Gly466Val) single nucleotide variant Pathogenic/Likely pathogenic rs121913351 GRCh37 Chromosome 7, 140481411: 140481411
35 BRAF NM_004333.4(BRAF): c.1790T> G (p.Leu597Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913366 GRCh37 Chromosome 7, 140453145: 140453145
36 BRAF NM_004333.4(BRAF): c.1405G> C (p.Gly469Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913357 GRCh37 Chromosome 7, 140481403: 140481403
37 BRAF NM_004333.4(BRAF): c.1406G> C (p.Gly469Ala) single nucleotide variant Pathogenic/Likely pathogenic rs121913355 GRCh37 Chromosome 7, 140481402: 140481402
38 BRAF NM_004333.4(BRAF): c.1781A> G (p.Asp594Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913338 GRCh37 Chromosome 7, 140453154: 140453154
39 BRAF NM_004333.4(BRAF): c.1406G> A (p.Gly469Glu) single nucleotide variant Pathogenic rs121913355 GRCh37 Chromosome 7, 140481402: 140481402
40 AKT1 NM_005163.2(AKT1): c.49G> A (p.Glu17Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121434592 GRCh37 Chromosome 14, 105246551: 105246551
41 GNAS NM_000516.5(GNAS): c.601C> T (p.Arg201Cys) single nucleotide variant Pathogenic/Likely pathogenic rs11554273 GRCh37 Chromosome 20, 57484420: 57484420
42 GNAS NM_000516.5(GNAS): c.602G> A (p.Arg201His) single nucleotide variant Pathogenic/Likely pathogenic rs121913495 GRCh37 Chromosome 20, 57484421: 57484421
43 FGFR3 NM_000142.4(FGFR3): c.742C> T (p.Arg248Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913482 GRCh37 Chromosome 4, 1803564: 1803564
44 EGFR NM_005228.4(EGFR): c.2573T> G (p.Leu858Arg) single nucleotide variant drug response rs121434568 GRCh37 Chromosome 7, 55259515: 55259515
45 EGFR NM_005228.4(EGFR): c.2155G> T (p.Gly719Cys) single nucleotide variant Pathogenic/Likely pathogenic,drug response rs28929495 GRCh37 Chromosome 7, 55241707: 55241707
46 CDK4 NM_000075.3(CDK4): c.70C> T (p.Arg24Cys) single nucleotide variant Pathogenic/Likely pathogenic,risk factor rs11547328 GRCh37 Chromosome 12, 58145431: 58145431
47 CTNNB1 NM_001904.3(CTNNB1): c.98C> A (p.Ser33Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121913400 GRCh37 Chromosome 3, 41266101: 41266101
48 CTNNB1 NM_001904.3(CTNNB1): c.110C> G (p.Ser37Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913403 GRCh37 Chromosome 3, 41266113: 41266113
49 CTNNB1 NM_001904.3(CTNNB1): c.98C> T (p.Ser33Phe) single nucleotide variant Pathogenic/Likely pathogenic rs121913400 GRCh37 Chromosome 3, 41266101: 41266101
50 CTNNB1 NM_001904.3(CTNNB1): c.101G> A (p.Gly34Glu) single nucleotide variant Pathogenic/Likely pathogenic rs28931589 GRCh37 Chromosome 3, 41266104: 41266104

Cosmic variations for Lung Cancer Susceptibility 3:

9 (show top 50) (show all 1869)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM48853 ZMYND10 lung,NS,carcinoma,adenocarcinoma c.622C>T p.R208C 23
2 COSM48854 ZMYND10 lung,NS,carcinoma,adenocarcinoma c.128A>G p.N43S 23
3 COSM95558 ZMYM2 lung,NS,carcinoma,adenocarcinoma c.95G>A p.G32E 23
4 COSM48850 ZAP70 lung,NS,carcinoma,adenocarcinoma c.1484C>T p.A495V 23
5 COSM95551 YWHAE lung,NS,carcinoma,adenocarcinoma c.146A>G p.Y49C 23
6 COSM49006 YES1 lung,NS,carcinoma,adenocarcinoma c.371+1G>T p.? 23
7 COSM48846 YES1 lung,NS,carcinoma,adenocarcinoma c.473G>T p.W158L 23
8 COSM94103 YBX3 lung,NS,carcinoma,adenocarcinoma c.655G>C p.A219P 23
9 COSM95540 WWP2 lung,NS,carcinoma,adenocarcinoma c.2280G>T p.W760C 23
10 COSM95537 WWP1 lung,NS,carcinoma,adenocarcinoma c.2098G>A p.D700N 23
11 COSM48844 WT1 lung,NS,carcinoma,adenocarcinoma c.668G>C p.S223T 23
12 COSM96290 WNT3 lung,NS,carcinoma,adenocarcinoma c.159C>A p.P53P 23
13 COSM96287 WNT16 lung,NS,carcinoma,adenocarcinoma c.156G>T p.L52L 23
14 COSM95520 WNT10A lung,NS,carcinoma,adenocarcinoma c.217G>A p.E73K 23
15 COSM95518 WNK2 lung,NS,carcinoma,adenocarcinoma c.1349C>A p.A450E 23
16 COSM95689 WNK1 lung,NS,carcinoma,adenocarcinoma c.3218C>G p.S1073* 23
17 COSM17658 VHL lung,NS,carcinoma,adenocarcinoma c.286C>T p.Q96* 23
18 COSM5369853 VHL lung,NS,carcinoma,adenocarcinoma c.514C>T p.P172S 23
19 COSM48841 VAV3 lung,NS,carcinoma,adenocarcinoma c.1852C>G p.Q618E 23
20 COSM48840 VAV3 lung,NS,carcinoma,adenocarcinoma c.2519C>A p.S840Y 23
21 COSM48839 VAV2 lung,NS,carcinoma,adenocarcinoma c.301G>T p.D101Y 23
22 COSM48838 VAV2 lung,NS,carcinoma,adenocarcinoma c.428G>T p.R143L 23
23 COSM48837 VAV1 lung,NS,carcinoma,adenocarcinoma c.2402T>C p.L801P 23
24 COSM95504 VAV1 lung,NS,carcinoma,adenocarcinoma c.1551C>A p.D517E 23
25 COSM48836 VAV1 lung,NS,carcinoma,adenocarcinoma c.175G>A p.E59K 23
26 COSM95743 USP4 lung,NS,carcinoma,adenocarcinoma c.2645-1G>C p.? 23
27 COSM95460 USP33 lung,NS,carcinoma,adenocarcinoma c.1219A>G p.R407G 23
28 COSM95461 USP33 lung,NS,carcinoma,adenocarcinoma c.1151A>G p.D384G 23
29 COSM95456 USP31 lung,NS,carcinoma,adenocarcinoma c.1681G>T p.D561Y 23
30 COSM96263 USP22 lung,NS,carcinoma,adenocarcinoma c.1399C>T p.L467L 23
31 COSM96261 USP20 lung,NS,carcinoma,adenocarcinoma c.477C>T p.A159A 23
32 COSM95684 USP19 lung,NS,carcinoma,adenocarcinoma c.1190C>G p.S397* 23
33 COSM95839 UBR5 lung,NS,carcinoma,adenocarcinoma c.8328C>G p.L2776L 23
34 COSM94157 UBR5 lung,NS,carcinoma,adenocarcinoma c.3368G>T p.G1123V 23
35 COSM94156 UBR5 lung,NS,carcinoma,adenocarcinoma c.3554G>T p.G1185V 23
36 COSM94154 UBR5 lung,NS,carcinoma,adenocarcinoma c.4739G>T p.G1580V 23
37 COSM48833 TYK2 lung,NS,carcinoma,adenocarcinoma c.3545C>T p.S1182L 23
38 COSM48834 TYK2 lung,NS,carcinoma,adenocarcinoma c.3206C>G p.A1069G 23
39 COSM95422 TYK2 lung,NS,carcinoma,adenocarcinoma c.1181G>A p.S394N 23
40 COSM95418 TTK lung,NS,carcinoma,adenocarcinoma c.2245G>T p.D749Y 23
41 COSM48829 TSHR lung,NS,carcinoma,adenocarcinoma c.18G>T p.L6F 23
42 COSM48830 TSHR lung,NS,carcinoma,adenocarcinoma c.1555C>A p.R519S 23
43 COSM48831 TSHR lung,NS,carcinoma,adenocarcinoma c.1966G>A p.V656I 23
44 COSM48827 TSC2 lung,NS,carcinoma,adenocarcinoma c.1923C>A p.S641R 23
45 COSM48826 TSC2 lung,NS,carcinoma,adenocarcinoma c.1414G>A p.V472M 23
46 COSM48828 TSC2 lung,NS,carcinoma,adenocarcinoma c.3867G>T p.R1289S 23
47 COSM95412 TSC1 lung,NS,carcinoma,adenocarcinoma c.193C>G p.Q65E 23
48 COSM48825 TSC1 lung,NS,carcinoma,adenocarcinoma c.611G>T p.R204L 23
49 COSM95403 TRIM33 lung,NS,carcinoma,adenocarcinoma c.1812G>T p.R604S 23
50 COSM95404 TRIM33 lung,NS,carcinoma,adenocarcinoma c.379G>A p.V127M 23

Copy number variations for Lung Cancer Susceptibility 3 from CNVD:

7 (show top 50) (show all 580)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13394 1 1 2300000 Gain Lung adenocarcinoma
2 13409 1 1 2300000 Gain Lung adenocarcinoma
3 13970 1 102000000 107000000 Loss Lung adenocarcinoma
4 13986 1 102200000 107200000 Loss Lung adenocarcinoma
5 14528 1 109314358 109386258 Deletion WDR47 Lung adenocarcinoma
6 15384 1 115048600 115061038 Copy number NRAS Lung adenocarcinoma
7 17560 1 143480000 149410000 Amplification ARNT Lung adenocarcinoma
8 18143 1 144218994 144222801 Amplification RBM8A Lung adenocarcinoma
9 18161 1 144227739 144235088 Amplification PEX11B Lung adenocarcinoma
10 18176 1 144287344 144297903 Amplification PIAS3 Lung adenocarcinoma
11 18223 1 144475951 145932379 Amplification GPR89A Lung adenocarcinoma
12 18385 1 145180914 145234067 Amplification CHD1L Lung adenocarcinoma
13 18405 1 145479805 145564639 Amplification BCL9 Lung adenocarcinoma
14 18433 1 145585791 145609258 Amplification ACP6 Lung adenocarcinoma
15 19003 1 148137824 148138969 Amplification BOLA1 Lung adenocarcinoma
16 19039 1 148305965 148384129 Amplification VPS45 Lung adenocarcinoma
17 19152 1 148885329 148936257 Amplification GOLPH3L Lung adenocarcinoma
18 19199 1 149165511 149203837 Amplification SETDB1 Lung adenocarcinoma
19 19207 1 149221122 149234738 Amplification ANXA9 Lung adenocarcinoma
20 19214 1 149247596 149274813 Amplification PRUNE Lung adenocarcinoma
21 19280 1 149399337 149404960 Amplification LYSMD1 Lung adenocarcinoma
22 19287 1 149415557 149429264 Amplification VPS72 Lung adenocarcinoma
23 19299 1 149493820 149506578 Amplification PSMD4 Lung adenocarcinoma
24 19341 1 149638664 149641036 Amplification PSMB4 Lung adenocarcinoma
25 19375 1 149998746 150002664 Amplification MRPL9 Lung adenocarcinoma
26 19378 1 150009206 150029634 Amplification TDRKH Lung adenocarcinoma
27 19432 1 150271605 150276135 Amplification S100A11 Lung adenocarcinoma
28 20047 1 152787674 152797744 Amplification UBE2Q1 Lung adenocarcinoma
29 20052 1 152821157 152867061 Amplification ADAR Lung adenocarcinoma
30 20569 1 153196125 153200882 Amplification PYGO2 Lung adenocarcinoma
31 20571 1 153201397 153213464 Amplification SHC1 Lung adenocarcinoma
32 20591 1 153213790 153218346 Amplification CKS1B Lung adenocarcinoma
33 20592 1 153222440 153232211 Amplification FLAD1 Lung adenocarcinoma
34 20617 1 153302836 153308653 Amplification EFNA4 Lung adenocarcinoma
35 20622 1 153317971 153326638 Amplification EFNA3 Lung adenocarcinoma
36 20838 1 154761820 154809020 Amplification IQGAP3 Lung adenocarcinoma
37 20853 1 154828181 154830715 Amplification APOA1BP Lung adenocarcinoma
38 20863 1 154936029 154941999 Amplification CRABP2 Lung adenocarcinoma
39 20868 1 154959036 154964835 Amplification ISG20L2 Lung adenocarcinoma
40 20872 1 154973717 154977547 Amplification MRPL24 Lung adenocarcinoma
41 20875 1 154978522 155003341 Amplification HDGF Lung adenocarcinoma
42 20983 1 155749790 155788934 Amplification FCRL5 Lung adenocarcinoma
43 21047 1 156490550 156494682 Amplification CD1A Lung adenocarcinoma
44 21335 1 158163454 158182010 Amplification IGSF9 Lung adenocarcinoma
45 21364 1 158264085 158268407 Amplification PIGM Lung adenocarcinoma
46 21422 1 158525000 158579978 Amplification COPA Lung adenocarcinoma
47 21516 1 159308119 159325966 Amplification PVRL4 Lung adenocarcinoma
48 21522 1 159336969 159354490 Amplification PFDN2 Lung adenocarcinoma
49 21527 1 159354514 159361857 Amplification NIT1 Lung adenocarcinoma
50 21533 1 159390157 159395270 Amplification UFC1 Lung adenocarcinoma

Expression for Lung Cancer Susceptibility 3

LifeMap Discovery
Genes differentially expressed in tissues of Lung Cancer Susceptibility 3 patients vs. healthy controls: 35 (show all 45)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 TNNC1 troponin C type 1 (slow) Lung - 5.28 0.000
2 COL11A1 collagen, type XI, alpha 1 Lung + 5.07 0.000
3 MMP1 matrix metallopeptidase 1 Lung + 4.75 0.000
4 AGER advanced glycosylation end product-specific receptor Lung - 4.69 0.000
5 WIF1 WNT inhibitory factor 1 Lung - 4.60 0.000
6 SOSTDC1 sclerostin domain containing 1 Lung - 4.47 0.000
7 FABP4 fatty acid binding protein 4, adipocyte Lung - 4.32 0.000
8 CDH3 cadherin 3, type 1, P-cadherin (placental) Lung + 4.31 0.000
9 FOSB FBJ murine osteosarcoma viral oncogene homolog B Lung - 4.24 0.000
10 TMEM100 transmembrane protein 100 Lung - 4.20 0.000
11 CLEC3B C-type lectin domain family 3, member B Lung - 4.18 0.000
12 FCN3 ficolin (collagen/fibrinogen domain containing) 3 Lung - 4.17 0.000
13 MT1M metallothionein 1M Lung - 4.07 0.000
14 SPP1 secreted phosphoprotein 1 Lung + 4.04 0.000
15 SPINK1 serine peptidase inhibitor, Kazal type 1 Lung + 3.96 0.000
16 COL10A1 collagen, type X, alpha 1 Lung + 3.79 0.000
17 CLIC5 chloride intracellular channel 5 Lung - 3.65 0.000
18 ADIRF adipogenesis regulatory factor Lung - 3.65 0.000
19 RAMP2 receptor (G protein-coupled) activity modifying protein 2 Lung - 3.62 0.000
20 HIGD1B HIG1 hypoxia inducible domain family, member 1B Lung - 3.60 0.000
21 STXBP6 syntaxin binding protein 6 (amisyn) Lung - 3.59 0.000
22 TMPRSS4 transmembrane protease, serine 4 Lung + 3.53 0.000
23 EFCC1 EF-hand and coiled-coil domain containing 1 Lung - 3.47 0.000
24 MFAP4 microfibrillar-associated protein 4 Lung - 3.47 0.000
25 ABCC3 ATP-binding cassette, sub-family C (CFTR/MRP), member 3 Lung + 3.47 0.000
26 TOP2A topoisomerase (DNA) II alpha Lung + 3.41 0.000
27 TCF21 transcription factor 21 Lung - 3.38 0.000
28 CA4 carbonic anhydrase IV Lung - 3.38 0.000
29 CYP4B1 cytochrome P450, family 4, subfamily B, polypeptide 1 Lung - 3.33 0.000
30 GPM6A glycoprotein M6A Lung - 3.30 0.000
31 GINS2 GINS complex subunit 2 (Psf2 homolog) Lung + 3.29 0.000
32 NEK2 NIMA-related kinase 2 Lung + 3.27 0.000
33 TOX3 TOX high mobility group box family member 3 Lung + 3.24 0.000
34 IL1RL1 interleukin 1 receptor-like 1 Lung - 3.21 0.000
35 PKNOX2 PBX/knotted 1 homeobox 2 Lung - 3.21 0.000
36 ABCA8 ATP-binding cassette, sub-family A (ABC1), member 8 Lung - 3.17 0.000
37 SCGB1A1 secretoglobin, family 1A, member 1 (uteroglobin) Lung - 3.17 0.000
38 FIGF c-fos induced growth factor (vascular endothelial growth factor D) Lung - 3.14 0.000
39 CRABP2 cellular retinoic acid binding protein 2 Lung + 3.11 0.000
40 SGCG sarcoglycan, gamma (35kDa dystrophin-associated glycoprotein) Lung - 3.10 0.000
41 ADAMTS8 ADAM metallopeptidase with thrombospondin type 1 motif, 8 Lung - 3.08 0.000
42 SFTPD surfactant protein D Lung - 3.07 0.000
43 MARCO macrophage receptor with collagenous structure Lung - 3.07 0.000
44 COL1A1 collagen, type I, alpha 1 Lung + 3.05 0.000
45 NMU neuromedin U Lung + 3.05 0.000
Search GEO for disease gene expression data for Lung Cancer Susceptibility 3.

Pathways for Lung Cancer Susceptibility 3

Pathways related to Lung Cancer Susceptibility 3 according to GeneCards Suite gene sharing:

(show top 50) (show all 125)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.93 BRAF CASP3 CDH1 CDK4 EGFR ERBB2
2
Show member pathways
13.84 ACTR3B BRAF CDK4 EGFR ERBB2 HRAS
3
Show member pathways
13.77 BRAF CASP3 EGFR ERBB2 HRAS KRAS
4
Show member pathways
13.66 BRAF CDH1 EGFR ERBB2 HRAS KRAS
5
Show member pathways
13.63 BRAF CDK4 EGFR ERBB2 HRAS KRAS
6
Show member pathways
13.56 CDH1 EGFR ERBB2 HRAS KRAS PRKN
7
Show member pathways
13.49 BRAF CASP3 EGFR ERBB2 HRAS KRAS
8
Show member pathways
13.46 BRAF CASP3 EGFR HRAS KRAS RAF1
9
Show member pathways
13.39 BRAF CASP3 CDH1 EGFR ERBB2 HRAS
10
Show member pathways
13.32 BRAF EGFR ERBB2 HRAS KRAS RAF1
11
Show member pathways
13.16 BRAF EGFR HRAS KRAS RAF1 TP53
12
Show member pathways
13.13 BRAF EGFR HRAS KRAS RAF1 VEGFA
13
Show member pathways
13.12 BRAF CASP3 CDH1 HRAS KRAS RAF1
14
Show member pathways
13.1 CASP3 CDK4 EGFR HRAS KRAS RAF1
15
Show member pathways
13.05 BRAF EGFR ERBB2 HRAS KRAS RAF1
16
Show member pathways
13.04 BRAF CDH1 CDK4 HRAS KRAS RAF1
17
Show member pathways
13.04 BRAF EGFR ERBB2 HRAS KRAS RAF1
18
Show member pathways
13.03 BRAF CASP3 CDH1 CDK4 EGFR ERBB2
19
Show member pathways
12.99 BRAF CASP3 EGFR HRAS KRAS RAF1
20
Show member pathways
12.98 CASP3 HRAS KRAS RAF1 TP53
21 12.9 BRAF CASP3 EGFR HRAS KRAS RAF1
22
Show member pathways
12.9 BRAF CDH1 CDK4 EGFR ERBB2 HRAS
23
Show member pathways
12.87 BRAF CDH1 EGFR HRAS KRAS RAF1
24
Show member pathways
12.85 BRAF CASP3 CDH1 ERBB2 HRAS KRAS
25
Show member pathways
12.83 BRAF EGFR HRAS KRAS RAF1
26
Show member pathways
12.83 EGFR ERBB2 HRAS KRAS TP53
27
Show member pathways
12.8 CASP3 EGFR HRAS KRAS RAF1 VEGFA
28
Show member pathways
12.8 BRAF CASP3 EGFR HRAS KRAS RAF1
29
Show member pathways
12.77 BRAF EGFR HRAS KRAS RAF1
30 12.73 BRAF EGFR HRAS KRAS RAF1
31
Show member pathways
12.71 CASP3 CDK4 HRAS KRAS RAF1 TP53
32
Show member pathways
12.7 EGFR ERBB2 HRAS KRAS TP53
33
Show member pathways
12.67 BRAF CDK4 EGFR ERBB2 HRAS KRAS
34
Show member pathways
12.66 ACTR3B BRAF CDH1 EGFR RAF1
35
Show member pathways
12.65 ACTR3B BRAF CASP3 HRAS KRAS RAF1
36
Show member pathways
12.63 BRAF EGFR ERBB2 HRAS KRAS RAF1
37
Show member pathways
12.61 CASP3 ERBB2 HRAS KRAS RAF1
38 12.61 CASP3 EGFR ERBB2 HRAS KRAS RAF1
39
Show member pathways
12.6 BRAF EGFR ERBB2 HRAS KRAS RAF1
40
Show member pathways
12.58 CASP3 EGFR ERBB2 HRAS KRAS TP53
41
Show member pathways
12.54 BRAF CASP3 CDH1 EGFR ERBB2 HRAS
42
Show member pathways
12.53 BRAF HRAS KRAS RAF1 VEGFA
43
Show member pathways
12.5 EGFR HRAS KRAS RAF1 VEGFA
44
Show member pathways
12.49 EGFR HRAS KRAS RAF1
45
Show member pathways
12.47 BRAF HRAS KRAS RAF1
46
Show member pathways
12.46 HRAS KRAS RAF1 TP53
47 12.46 BRAF CASP3 CDH1 CDK4 EGFR ERBB2
48 12.44 CASP3 CDK4 HRAS KRAS TP53
49
Show member pathways
12.43 BRAF HRAS KRAS RAF1
50
Show member pathways
12.42 EGFR ERBB2 HRAS RAF1

GO Terms for Lung Cancer Susceptibility 3

Cellular components related to Lung Cancer Susceptibility 3 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.55 ACTR3B BRAF CASP3 CDH1 CDK4 EGFR
2 perinuclear region of cytoplasm GO:0048471 9.43 CDH1 CDK4 EGFR ERBB2 HRAS PRKN

Biological processes related to Lung Cancer Susceptibility 3 according to GeneCards Suite gene sharing:

(show all 28)
# Name GO ID Score Top Affiliating Genes
1 cell proliferation GO:0008283 9.98 EGFR ERBB2 HRAS RAF1 TP53
2 intracellular signal transduction GO:0035556 9.97 BRAF CASP3 EGFR ERBB2 RAF1 RASSF1
3 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.92 BRAF EGFR HRAS RAF1
4 autophagy GO:0006914 9.87 NAPSA PRKN STK11 TP53
5 cell cycle arrest GO:0007050 9.85 HRAS RASSF1 STK11 TP53
6 MAPK cascade GO:0000165 9.85 BRAF EGFR ERBB2 HRAS KRAS RAF1
7 negative regulation of neuron apoptotic process GO:0043524 9.84 BRAF HRAS KRAS PRKN
8 cellular response to drug GO:0035690 9.8 BRAF EGFR TP53
9 epidermal growth factor receptor signaling pathway GO:0007173 9.77 EGFR HRAS KRAS
10 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.76 BRAF EGFR RAF1 VEGFA
11 activation of MAPKK activity GO:0000186 9.75 BRAF EGFR RAF1
12 Ras protein signal transduction GO:0007265 9.73 HRAS KRAS RASSF1 TP53
13 positive regulation of epithelial cell proliferation GO:0050679 9.71 EGFR ERBB2 HRAS VEGFA
14 regulation of cell motility GO:2000145 9.69 EGFR ERBB2 RAF1
15 thyroid gland development GO:0030878 9.65 BRAF NKX2-1 RAF1
16 wound healing GO:0042060 9.65 CASP3 EGFR ERBB2 RAF1 TP53
17 cerebral cortex cell migration GO:0021795 9.64 EGFR NKX2-1
18 response to isolation stress GO:0035900 9.63 HRAS KRAS
19 positive regulation of protein phosphorylation GO:0001934 9.63 EGFR ERBB2 HRAS KRAS RAF1 VEGFA
20 surfactant homeostasis GO:0043129 9.62 NAPSA VEGFA
21 ERBB2 signaling pathway GO:0038128 9.62 EGFR ERBB2 HRAS KRAS
22 positive regulation of MAP kinase activity GO:0043406 9.35 EGFR ERBB2 HRAS KRAS VEGFA
23 positive regulation of gene expression GO:0010628 9.23 BRAF ERBB2 HRAS KRAS NKX2-1 PRKN
24 positive regulation of transcription by RNA polymerase II GO:0045944 10.14 EGFR HRAS NKX2-1 PRKN RAF1 TP53
25 phosphorylation GO:0016310 10.09 BRAF CDK4 EGFR ERBB2 RAF1 STK11
26 apoptotic process GO:0006915 10.08 CASP3 HRAS KRT20 RAF1 STK11 TP53
27 protein phosphorylation GO:0006468 10.03 BRAF CDK4 EGFR ERBB2 RAF1 STK11
28 negative regulation of apoptotic process GO:0043066 10 BRAF CASP3 EGFR RAF1 TP53 VEGFA

Molecular functions related to Lung Cancer Susceptibility 3 according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 kinase activity GO:0016301 9.93 BRAF CDK4 EGFR ERBB2 RAF1 STK11
2 protein kinase activity GO:0004672 9.8 BRAF CDK4 EGFR ERBB2 RAF1 STK11
3 enzyme binding GO:0019899 9.77 EGFR NKX2-1 PRKN RAF1 TP53
4 protein heterodimerization activity GO:0046982 9.73 BRAF EGFR ERBB2 RAF1 TP53 VEGFA
5 protein phosphatase binding GO:0019903 9.67 EGFR ERBB2 TP53
6 identical protein binding GO:0042802 9.56 BRAF CDH1 EGFR ERBB2 PRKN RAF1
7 signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 9.48 EGFR ERBB2
8 LRR domain binding GO:0030275 9.4 KRAS STK11
9 MAP kinase kinase kinase activity GO:0004709 9.33 BRAF EGFR RAF1
10 nucleotide binding GO:0000166 9.17 BRAF CDK4 EGFR ERBB2 HRAS KRAS
11 protein binding GO:0005515 10.44 BRAF CASP3 CDH1 CDK4 EGFR ERBB2
12 ATP binding GO:0005524 10.03 ACTR3B BRAF CDK4 EGFR ERBB2 RAF1

Sources for Lung Cancer Susceptibility 3

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....